Supreme Court Reviews ACA No-Cost Preventive Care Coverage Provision
Explore the Supreme Court case challenging the ACA's no-cost preventive care mandate, its implications for insurers, providers, and patient access to essential health services.
Explore the Supreme Court case challenging the ACA's no-cost preventive care mandate, its implications for insurers, providers, and patient access to essential health services.
CMS finalizes key elements of the CY 2026 Medicare Advantage and Medicare Part D final rule, including insulin coverage expansion, Prescription Payment Plan codification, pharmacy data requirements, and updated enrollee protections.
The Trump administration's 2026 draft budget proposes a one-third reduction in HHS funding, affecting NIH, CDC, CMS, and rural health programs, with key agency restructures and policy shifts.
Santa Cruz County health providers and nonprofits respond to federal Medicaid and social service funding cuts threatening coverage and community support.
Federal budget cuts targeting Medicare and Medicaid create challenges for Arizona's healthcare system, threatening rural hospitals and vulnerable populations dependent on AHCCCS coverage.
North Dakota House voted in favor of Senate Bill 2160 to revise state employee health insurance to align with ACA, aiming for cost savings and expanded preventive care without extra employee costs.
Recent study links Medicaid expansion under the Affordable Care Act to enhanced lung cancer treatment, with quicker surgeries at high-volume hospitals and better patient outcomes.
Wyoming's Supreme Court debates whether abortion is healthcare, impacting regulations and healthcare rights. This case exemplifies the broader discourse on reproductive health governance in the U.S.
In upstate New York, Medicare Advantage plan beneficiaries face possible cuts in benefits and increases in costs due to changes in the Medicare wage index. Learn about the legislative efforts to mitigate this issue.
The CMS final rule effective 2026 will modernize Medicare Advantage and Part D, enhancing drug coverage and establishing more robust regulatory frameworks.